Latest News

Biomarker-informed trial enrollment appears straightforward for identifying responders and optimizing efficiency, but failures to account for demographic variation in cut-off selection, causality versus correlation, and composite biomarker complexity risk excluding viable patients and exacerbating disparities.

In this video interview, Patrick Mizer, chief technology officer at Ledger Run, addresses the reality that 80% of sites operate on six months or less of cash—and explains why growing investment in agentic AI and workflow modernization signals that the industry is starting to treat payment infrastructure as the priority it deserves.

In today's ACT Brief, we examine how unpredictable payments damage site retention, why rapid AI deployment without validation creates regulatory risk, and China's growing dominance in early-stage drug discovery.

In this video interview, Patrick Mizer, chief technology officer at Ledger Run, explains how unpredictable payments erode site relationships over time—and why operational excellence in payments is becoming increasingly important to landing and retaining the best investigative sites.

AI is reshaping clinical research faster than any technology before it; but for sponsors and CROs, adoption without GxP-grade governance, validation, and human oversight isn't a strategy. It's a risk.

In today's ACT Brief, we examine where agentic AI delivers immediate wins in site payments, how botanical therapies can earn pharmaceutical credibility, and the connected financial systems reshaping trial operations.

As trials grow more global and complex, fragmented financial systems are becoming a liability. Connecting them with AI is the next operating model for clinical trial finance.

In this episode of Beyond Compliance, Otis Johnson, PhD, MPA, founder and principal consultant at Vantix Operations, speaks with Joel Stanley, CEO of AJNA BioSciences, about why botanical therapies need pharmaceutical-grade standardization and clinical evidence to earn physician trust and insurance coverage.

In this video interview, Patrick Mizer, chief technology officer at Ledger Run, describes how agentic AI is being applied to invoice processing—one of the most labor-intensive bottlenecks in site payments—and what meaningful improvement actually looks like in practice.

Inspection readiness reflects how a program was actually run throughout its lifecycle, not what can be assembled at the end, making pre-submission remediation itself a signal of absent oversight rather than proof of it.

In this video interview, Patrick Mizer, chief technology officer at Ledger Run, traces the fragmented contracts, outdated benchmarks, and disconnected systems behind payment inconsistency—and explains why the industry has historically accepted the complexity rather than addressed it.

In today's ACT Brief, we examine how payment reliability has become a competitive differentiator at high-performing sites, what a truly strategic lean development model looks like, and a licensing deal for a next-generation obesity therapy combining Phase I data with preclinical validation.

In this video interview, Patrick Mizer, chief technology officer at Ledger Run, explains how the shift from competing for patients to competing for high-performing sites has made payment reliability an operational brand—and a real factor in which sponsors get prioritized.